Here we provide the first evidence that tetraspanin CD151 can support de novo carcinogenesis. During two-stage mouse skin chemical carcinogenesis, CD151 reduces tumor lag time and increases incidence, multiplicity, size and progression to malignant squamous cell carcinoma (SCC), while supporting both cell survival during tumor initiation and cell proliferation during the promotion phase. In human skin SCC, CD151 expression is selectively elevated compared with other skin cancer types. CD151 support of keratinocyte survival and proliferation may depend on activation of transcription factor STAT3 (signal transducers and activators of transcription), a regulator of cell proliferation and apoptosis. CD151 also supports protein kinase C (PKC)a-a6b4 integrin association and PKC-dependent b4 S1424 phosphorylation, while regulating a6b4 distribution. CD151-PKCa effects on integrin b4 phosphorylation and subcellular localization are consistent with epithelial disruption to a less polarized, more invasive state. CD151 ablation, while minimally affecting normal cell and normal mouse functions, markedly sensitized mouse skin and epidermoid cells to chemicals/drugs including 7,12-dimethylbenz[a]anthracene (mutagen) and camptothecin (topoisomerase inhibitor), as well as to agents targeting epidermal growth factor receptor, PKC, Jak2/Tyk2 and STAT3. Hence, CD151 'co-targeting' may be therapeutically beneficial. These findings not only support CD151 as a potential tumor target, but also should apply to other cancers utilizing CD151/laminin-binding integrin complexes.
INTRODUCTION
Cell surface protein CD151, a tetraspanin protein family member, is expressed in epithelial, endothelial, Schwann and dendritic cells, and in skeletal, smooth and cardiac muscle.
1 CD151 associates closely with laminin-binding integrins (that is, a3b1, a6b1, a6b4 and a7b1) and modulates their functions. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] CD151-null mice are mostly viable, healthy and fertile. 13 However, humans and mice (in particular strains, and under specific conditions) lacking CD151 have kidney and skin deficiencies. [14] [15] [16] [17] Absence of laminin-binding integrins also causes kidney and skin pathology, 18 consistent with CD151 being functionally linked to laminin-binding integrins. CD151 may affect functions of laminin-binding integrins by regulating integrin diffusion, 19 glycosylation 20 and/or internalization. 21 Also, CD151 can recruit proteins such as phosphoinositide 4-kinase, protein kinase C (PKC) and other tetraspanins (for example, CD9, CD81, CD82, CD63) into complexes with laminin-binding integrins, 11, 22, 23 which potentially affects integrin functions. 24 Because laminin and laminin-binding integrins contribute both negatively and positively to carcinogenesis, [25] [26] [27] [28] CD151 conceivably could also play negative and/or positive roles. For example, integrin a6b4 suppresses tumor-initiating mouse skin cell growth 29 and induces apoptosis in carcinoma cells expressing p53. 30 Hence, while supporting a6b4, CD151 might inhibit early carcinogenesis stages. Alternatively, studies with cancer cell lines show CD151 contributing to epidermoid carcinoma cell migration and metastasis, 31 breast cancer cell invasion and migration in vitro, and breast tumor xenograft growth in vivo. 32, 33 Also, CD151 in host tissues facilitates tumor angiogenesis, 34 and tumor cell CD151 supports ErbB2 drug resistance in cells plated on specific laminin isoforms. 35 CD151 has not previously been reported to affect de novo carcinogenesis or specific stages of carcinogenesis (that is, initiation, promotion, progression). Furthermore, there is little precedent from studies of related molecules (that is, other tetraspanin proteins) for regulation of early carcinogenesis stages.
To evaluate CD151's role during de novo carcinogenesis, we used two-stage skin chemical carcinogenesis. 36 During skin tumor initiation, carcinogen DMBA (7,12-dimethylbenz[a] anthracene) is metabolized to reactive diol-epoxides that bind to DNA and mutate target keratinocytes. Initiated cells escaping DNA repair and apoptosis may clonally expand during TPA (12-Otetradecanoyl phorbol 13-acetate)-induced tumor promotion. This model is ideally suited for investigating CD151 functions in de novo carcinogenesis at specific carcinogenesis stages. Furthermore, mouse skin chemical carcinogenesis results are relevant to human skin SCC. 36, 37 Among epidermoid carcinomas, squamous cell carcinoma (SCC) is one of the most common forms of cancer in the United States. There are B250,000 new cases/ year, 38 with 2-9.9% metastasis incidence, which leads to poor long-term prognosis. 39 We show significant and selective CD151 upregulation on human skin SCC samples. Also CD151 knockout mice, subjected to skin chemical carcinogenesis, showed extended tumor latency and decreased tumor incidence, multiplicity and size. Furthermore, CD151 contributed during the skin tumor initiation, promotion and progression stages, and supported chemical/drug resistance. Also we provide mechanistic insights involving CD151 effects on STAT3, PKCa and integrin a6b4. These results are relevant not only toward understanding human skin SCC, but also for other epithelial cancers similarly using CD151-integrin complexes.
RESULTS

CD151 elevation in human skin SCC
To assess CD151 protein expression in human skin tumors, we examined 83 skin cancer microarray samples. Representative images (Figures 1a-c) show abundant CD151 staining of human skin SCC samples, especially at cell membranes, with also some intracellular staining (Figure 1b) . In normal human skin, CD151 is abundant only in basal and parabasal cell layers (Figure 1c , left panel). Most human skin SCC samples showed elevated CD151 staining (67% with score of 41; Figure 1d ). Samples from grade II SCC trended toward more elevated CD151 staining (score ¼ 3, n ¼ 14), compared with grade I SCC (score ¼ 2.35, n ¼ 36, P ¼ 0.1). Contrasting with skin SCC, other skin cancer types showed weak staining. Staining scores were 1 ( Figure 1d ) for most basal cell carcinomas (92%), metastatic melanoma (91%) and dermatofibrosarcoma protuberans (100%) samples. Overall, CD151 is selectively and significantly elevated in human skin SCC compared with other skin tumors (Figure 1d ; mean scores in right panel), and thus is well positioned for significant functional contributions.
Response of CD151-null mice to two-stage carcinogenesis To address CD151 functions, we used a two-stage mouse chemical carcinogenesis protocol, which models human skin SCC initiation, promotion and progression.
36 CD151 wild-type, heterozygous and null mice (129/Sv strain) were backcrossed four generations into FVB/N background, which is substantially more sensitive to skin tumor formation. 40 Mice were treated once with initiating agent DMBA (100 nmol), and then weekly with 8 nmol TPA. Figure 2a shows markedly reduced tumor development in CD151-null mice, compared with þ / þ and þ / À mice. Tumors appeared in most þ / þ mice by 7 weeks, in significantly greater numbers (up to 14 per mouse). By contrast, -/-mouse tumors appeared later (after 9 weeks) and less frequently (2-4 per mouse; Figures 2a-c), and were smaller (Figure 2d ). Tumor appearance, multiplicity and size were only partly impaired in CD151 þ /-compared with CD151 þ / þ mice (Figures 2a-d) . After 20 weeks, 6.4% of þ / þ mouse tumors showed conversion to malignant SCC. By contrast, malignant conversion was significantly reduced for þ / À (2.3%) and À / À (0%) mouse tumors, as judged by histological analysis (Table 1) . In summary, CD151 contributes to mouse skin tumor appearance, multiplicity, size and malignant conversion.
CD151 contributions during tumor initiation and promotion stages Before treatment, þ / þ and -/-mouse skin differed minimally in apoptosis (seen by caspase staining of epidermis; Figures 3A and B), epidermal proliferation (Figures 4c and d) and epidermal STAT3 activation (Figures 5c and d) . Also, morphology and epidermal thickness was essentially identical, as seen in hematoxylin and eosin-stained cross-sections of dermis and epidermis (Figure 4a ). In addition, untreated þ / þ and -/-primary keratinocytes showed essentially identical background apoptosis ( Figure 3C ).
To determine CD151 effects on keratinocytes during tumor initiation, we treated mouse skin with DMBA alone, and then intact skin sections were assessed for apoptosis by caspase-3 staining. DMBA treatment stimulated more keratinocyte apoptosis in CD151-null mice ( Figures 3A and B) . Cultured CD151-null keratinocytes also showed increased DMBA-induced apoptosis ( Figure 3C ). Another type of DNA-damaging agent, camptothecin, also increased apoptosis in CD151-null keratinocytes ( Figure 3C ). Thus, CD151-/-keratinocytes appear sensitized to chemical stress.
To study tumor promotion, mice were treated four times with TPA, over 2 weeks, without prior DMBA treatment. Epidermal thickness increased to a lesser extent in CD151-/-mice ( Figures  4a and b) . Likewise, CD151-/-mice incorporated 45% less bromodeoxyuridine (BrdU; Figures 4c and d) . Thus, reduced tumor development in CD151-null skin may arise from changes in both DMBA-induced apoptosis and TPA-induced proliferation.
CD151 affects STAT3 activation STAT3, a transcription factor constitutively active in many human malignancies, 41 is essential for epidermal survival and proliferation during skin carcinogenesis leading to SCC. 42, 43 Mouse skin cell lines derived from CD151-/-papillomas showed 40-60% less activated STAT3, while total STAT3 was unchanged (Figure 5a ). Following treatment with DMBA alone (as in Figure 3A ), mouse skin samples were lysed and analyzed for STAT3 activation. Again, STAT3 was less activated in samples from CD151-/-mice (Figure 5c ), suggesting that loss of STAT3 activation contributes to increased apoptosis ( Figures 3A and B) . After mouse skin treatment with TPA alone (as in Figure 4 ), STAT3 activation substantially increased in CD151 þ / þ , but not CD151-/-mouse samples (Figure 5d ). Thus, failure to increase STAT3 activation may contribute to diminished epidermal proliferation in CD151-/-skin. The presence or absence of CD151 minimally affected total STAT3 levels (Figures 5c and d) .
CD151-null cultured primary keratinocytes showed diminished proliferation (measured two different ways; Figure 6a ), likely due to diminished response to EGF in keratinocyte growth media. This difference disappeared upon cell treatment (for 2-3 days) with nifuroxazide, which inhibits Jak2 and Tyk2 kinases immediately upstream of STAT3, 45 consistent with CD151 functions depending on STAT3. Results in Figure 6b confirm that nifuroxazide indeed inhibits STAT3 activation in both CD151-null and control cells.
Next we found that CD151 affects the entire epidermal growth factor receptor (EGFR)-Jak2/Tyk2-STAT3 signaling pathway, as evidenced by enhanced drug sensitivity in CD151-ablated cells, using a STAT3 activation readout. Indeed, in papilloma-derived mouse skin cell lines lacking CD151, potency of nifuroxazide inhibition of STAT3 activation was enhanced (Supplementary Figure S1A ). To explore this further, we analyzed STAT3 activation in A431 cells. In untreated cells, CD151 ablation minimally affected STAT3 activation. However, CD151 absence markedly enhanced sensitivity to nifuroxazide. STAT3 activation in control A431 cells was relatively unaffected by 2-5 mM nifuroxazide (Figure 6c , Supplementary Figure S2A ). By contrast, CD151-ablated cells were sensitized, showing markedly diminished STAT3 activation, especially 5 h after treatment at the higher nifuroxazide dose. Using EGFR inhibitor lapatinib, 46 we again saw CD151 ablation increasing drug sensitivity, resulting in greater loss of constitutive STAT3 activation ( CD151 has been suggested to affect c-MET signaling, b4 integrin collaboration and support of tumor xenograft growth, 47 and c-MET may signal through STAT3. 48 However, using c-MET inhibitor su11274, 49 we did not see altered STAT3 activation ±CD151 ablation (Supplementary Figure S3A) . A consistent 25-30% decrease in c-MET activation affirms that su11274 is functional (Supplementary Figure S3A CD151 affects b4 integrin phosphorylation Among laminin-binding integrins, a6b4 makes critical contributions during skin cancer progression to SCC. 29, 50, 51 CD151 affects subcellular distribution of tumor cell a6b4. 33 Indeed, within CD151-/-skin tumor cells, b4 integrin was considerably more punctate and/or distributed toward the cell periphery. By contrast, CD151 þ / þ cell b4 was distributed more diffusely ( Figure 7a ). Also, CD151-/-cells were less well spread, and less tightly clustered ( Figure 7a ). Similarly, cultured primary CD151-/-keratinocyte b4 was more distributed to the cell periphery ( Figure 7b ).
During keratinocyte carcinogenesis, EGF/TPA stimulates b4 serine phosphorylation at key sites, including S1424 52 and S1356. 50, 53 This enables b4 dissociation from the intermediate filament cytoskeleton, as hemidesmosomes are disrupted and epithelial cells lose polarity while becoming more invasive. 50, 52, 53 Reagents were unavailable for analyzing mouse serine site-specific b4 phosphorylation. However in CD151-ablated human A431 cells, S1424 phosphorylation was notably impaired in response to TPA (38% of wild type) or EGF (51% of wild type; Figure 7c ). By contrast, b4 S1356 phosphorylation was similarly stimulated by TPA and EGF, regardless of CD151 presence (Figure 7c , second row).
CD151 affects conventional PKC location and function Phosphorylation of b4 at S1424, 52 but not S1356, 54 requires conventional PKC (cPKC) isoforms. Integrin b4 in A431 cells coimmunoprecipitated with a cPKC isoform (PKCa) after cell stimulation with phorbol ester or EGF for 5-60 min. However, PKCa-a6b4 association was markedly diminished (especially 5 min after TPA or EGF stimulation) if CD151 was ablated, even though equal amounts of b4 and PKCa were retained (Figure 8a ). These results are consistent with CD151 linking PKCa to a6b4. We also addressed cPKC effects on STAT3 activation. As indicated (Figure 8b ), cPKC inhibitor Go6976 markedly inhibited STAT3 activation in CD151-ablated A431 cells, but not in control cells. The PKC inhibitor did not affect total levels of STAT3 and PKCa.
Possible indirect effects of CD151 on skin tumor formation As CD151 can support tumor angiogenesis, 34 we considered that CD151 ablation may diminish chemical carcinogenesis due to decreased angiogenesis. However, mouse skin tumor microarray analyses revealed no decrease, in CD151-null tumors, in VEGF or CD31 expression (Supplementary Table 1 ). Furthermore, wild-type and null tumor vessel densities did not differ. [55] [56] [57] [58] [59] However, levels of cytokines (IL-6, IL-12, IL-17, IL-23) in skin did not change upon CD151 ablation (Supplementary Table 2 ). Furthermore, CD151 ablation caused no decrease in IL-6-stimulated activation of TYK2 (Supplementary Figure 1c) , a major cytokineresponsive STAT3-activating kinase. 60 Likewise, IL-6-induced STAT3 activation was undiminished in mouse keratinocytes lacking CD151 (Supplementary Figure 1c) . Hence, CD151 removal does not perturb major cytokine networks important for regulating STAT3 and skin carcinogenesis.
DISCUSSION
On the basis of the prior studies (see Introduction), it was unclear whether CD151 would positively or negatively affect de novo tumor formation. Here we show that during mouse chemical carcinogenesis CD151: reduced tumor lag time; promoted tumor incidence, multiplicity, size and progression to SCC; contributed to both tumor initiation and promotion stages, and markedly altered signaling through b4 integrin, EGFR, PKCa and STAT3.
CD151 and skin SCC Although many epithelial tumor types upregulate CD151, 32, 33, [61] [62] [63] appearance on human skin SCC had not been reported. Tissue microarray data now show that CD151 selectively upregulated in human skin SCC, but not in other human skin tumors (basal cell carcinoma, metastatic melanoma, dermatofibrosarcoma protuberans). Laminin-binding integrins are not known to play major roles in those other skin cancers, which may explain lack of CD151 upregulation. Although CD151 trended toward elevated expression in higher grade skin SCC, patient prognosis data were unavailable. However, CD151 associates with poor patient prognosis in breast cancer and other cancers, 32, [61] [62] [63] and correlates with metastasis in esophageal SCC. 47 CD151 is not only present, but also is a key contributor in the genesis of skin SCC, as seen using a mouse model that has previously yielded many results relevant to multistage genesis of human epithelial cancers, including skin SCC. 36, 37 CD151 effects during the tumor initiation stage The absence of CD151 markedly enhanced apoptosis induced by DMBA (during carcinogenesis initiation) and by camptothecin Increased DMBA-induced apoptosis in CD151-null keratinocytes was accompanied by decreased STAT3 activation. This result helps explain reduced CD151-null skin tumor formation, because STAT3 activation plays a major role during chemical carcinogenesis initiation. 43 Decreased STAT3 activation accompanies decreased resistance to multiple types of cellular stresses. 67 In this regard, CD151 removal enhanced sensitivity to DMBA (a mutagen), camptothecin (an inducer of DNA fragmentation) and to STAT3 pathway inhibitors, thus indicating general chemical stress sensitization. Decreased STAT3 activity in keratinocytes might arise not only from decreased activation, but also from enhanced deactivation, due to phosphatases, 68 which would be consistent with our results.
CD151 and tumor promotion Mice (and cells) lacking CD151 showed major decreases in TPAinduced epidermal hyperplasia, epidermal cell proliferation and STAT3 activation, thus further explaining diminished tumor yield during two-stage carcinogenesis. Mouse skin TPA responses require a functioning EGFR. 69 Integrin a6b4 may associate physically and/or functionally with the EGFR, 70 with CD151 also supporting EGFR functions. 33 In this regard, CD151 ablation diminished b4 phosphorylation responses to both TPA and EGF (Figure 7c ). Hence EGFR disruption, due to CD151 removal, may explain diminished TPA responses.
SCC tumor promotion during chemical carcinogenesis requires STAT3 activation. 43 Thus, impaired TPA-induced STAT3 activation (and/ or enhanced TPA-induced STAT3 inactivation) may be central to diminished tumor promotion and skin tumor formation in CD151-null mice. Because the EGFR makes major contributions to STAT3 activation during tumor promotion, 69 loss of CD151-integrin regulation of the EGFR should contribute to diminished STAT3 activation. Disrupted recruitment of PKCa also likely contributes to diminished TPA induction of STAT3 activation in CD151-ablated cells (next section).
CD151 and tumor progression CD151-null mouse tumors did not progress to SCC. As activated STAT3 promotes malignant progression during chemical carcinogenesis, 42 reduced STAT3 activation likely underlies absence of CD151-null tumor progression. SCC may arise from keratinocyte stem cells, 71 implying that stem cell oncogenesis could be deficient in CD151-null mice. As a6 integrins serve as keratinocyte stem cell markers, 72 CD151 is well positioned to possibly contribute to stem cell oncogenesis.
CD151 effects on PKCa
Besides disrupting a6b4-EGFR collaborations, CD151 ablation also impairs a6b4-PKC connections. TPA stimulation activates cPKC CD151 in human and mouse skin cancer Q Li et al isoforms, such as PKCa in skin. 73 Hence, PKCa dysregulation could underlie deficient TPA stimulation in the absence of CD151. TPA (and EGF) stimulate PKCa-dependent phosphorylation of b4 at S1424. 52 Phosphorylation of b4 S1424 (and three other serines) contributes to b4 dissociation from intermediate filament hemidesmosomes, while switching to an actin-connected invasive state. 50, 53, 74 Hence, diminished S1424 phosphorylation, due to CD151 absence, is consistent with the maintenance of a6b4 in a more intermediate filament-anchored state, less susceptible to epithelial disruption and less likely to increase invasion. Shifting of b4 in keratinocytes and mouse tumor lines toward a peripheral/punctate staining pattern appears consistent with diminished hemidesmosomes association. Unfortunately, antibody specific for mouse b4 S1424 was not available to confirm expected loss of S1424 phosphorylation in mouse cells.
Phosphorylation of b4 at S1356, which is independent of cPKC isoforms, 54 was unaffected by CD151 absence, thus emphasizing selective CD151 support for PKCa function. Only when CD151 was present did we observe TPA stimulation of PKCa association with a6b4, thus supporting a role for CD151 in recruiting PKCa into proximity with a6b4. Previously CD151 was shown to recruit, upon TPA stimulation, cPKC isoform PKCbII into proximity with laminin-binding integrins. 23 Selective loss of PKCa recruitment to a6 integrins could explain not only diminished b4 S1424 phosphorylation, but also other impaired TPA-stimulated functions (that is, epidermal proliferation and STAT3 activationsee Figure 9 ). CD151 and STAT3 CD151 had not previously been linked to STAT3 signaling. Integrin a6b4 may signal through STAT3 in ErBB2-driven breast cancer cells, but this did not involve proliferation or apoptosis. 26 Hence, our results uncover a new link between CD151-a6b4 complexes and STAT3 signaling during the tumor initiation and promotion stages.
Several findings point to CD151 acting through STAT3 during skin tumor formation. First, activated STAT3 is essential for tumor progression in the DMBA/TPA model. 42 Hence, decreased STAT3 activation, due to CD151 removal, must affect tumor progression. Second, inhibition of STAT3 eliminated CD151 effects on proliferation (see Figure 6a) , thus linking CD151 functions to STAT3. Third, STAT3 is required for skin tumor initiation and tumor promotion. 43 Therefore, diminished STAT3 activation caused by CD151 absence can explain contributions of CD151 during tumor initiation and tumor promotion stages.
Are CD151 effects 'keratinocyte-specific'? CD151 effects on skin tumor formation appear to be largely 'keratinocyte-specific'. Decades of research show that skin CD151 in human and mouse skin cancer Q Li et al chemical carcinogenesis initiation and promotion occur entirely through keratinocyte mutation and selection. 36, 37 Furthermore, CD151 ablation from purified epidermoid cell populations definitively alters cell survival, proliferation, STAT3 activation, STAT3 drug sensitivity, integrin b4 distribution and phosphorylation, and b4-PKC association (consistent with altered TPA response).
We considered that CD151 on other cell types might affect skin tumor formation by altering angiogenesis, 34 immune cell functions 75 or cytokines that activate STAT3. [55] [56] [57] [58] [59] However, key cytokine levels in skin were unchanged, and evidence obtained thus far does not support altered angiogenesis. In this regard, implanted melanoma cells did not show altered angiogenesis when CD151 was absent from the host. 34, 65 Furthermore, immune cells in CD151-ablated tumor-bearing mice were unaltered with respect to tumor infiltration, subset sizes, activation or trafficking. 65 In conclusion, available data point to keratinocyte CD151 as being largely responsible for supporting chemical carcinogenesis.
Summary and broader implications CD151 absence had no detectable effect on normal mouse skin morphology or histology, as seen previously 13, 17 and confirmed here. However, CD151 absence markedly diminished cell survival during tumor initiation, proliferation during the promotion phase and progression to SCC. A pattern has emerged in which CD151 may be dispensable for normal physiological processes, while contributing to pathological events. For example, CD151 is unnecessary for normal development of blood vessels and skin in C57Bl6 mice, 13, 34 but plays a critical role during pathological events such as tumor angiogenesis, 34 skin wound healing 15 and skin tumor formation (shown here). Because CD151 effects are more obvious in pathological compared to normal situations, CD151 prospects as a tumor target are enhanced.
Neoplastic transformation in many cell types is supported by activated STAT3 41 and by a6 integrins (for example, Guo et al. 26 ), which invariably associate with CD151. Hence, CD151 should contribute to de novo tumor formation, progression and STAT3 activation in many other epithelial cancers. CD151 contributions to (a) cell survival during tumor initiation, (b) cell proliferation during tumor promotion and (c) tumor progression, represent major additions to the growing list of CD151 cancer roles, during angiogenesis, 34 tumor metastasis, 31 tumor xenograft growth 32, 33 and on stem-like prostate tumor-initiating cells. 76 Consequently, targeting CD151 should have multi-pronged anticancer effects. Also, because CD151 removal sensitizes tumor cells to agents targeting EGFR/ErbB2, STAT3 and PKCa, co-targeting of CD151 may enhance effectiveness of other agents directed at a6 integrins and associated signaling pathways. 44 and then STAT3 activity was determined as indicated in Supplementary Figure S2B . WT, wild type.
MATERIALS AND METHODS
CD151 in human and mouse skin cancer Q Li et al Cells, antibodies, chemicals and short hairpin RNA A431 cells were maintained in Dulbecco's modified Eagle's medium, 10% fetal calf serum, at 37 1C in humidified 5% CO 2 . Mouse tumor-derived cell lines were cultured in Dulbecco's modified Eagle's medium/F12, containing 5% fetal calf serum, 5 mg/ml insulin, 100 ng/ml Cholera toxin, 10 mM HEPES, 1 mg/ml hydrocortisone and 10 ng/ml EGF. Anti-b-actin was from SigmaAldrich (St Louis, MO, USA), anti-STAT3 and anti-PKCa were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and anti-pSTAT3(Tyr 705 ) was from Cell Signaling Technologies (Beverly, MA, USA). Monoclonal antibodies to CD151 were 5C11, 11 1A5 (gift from A Zijlstra) and RLM30 (Leica Microsystems, Buffalo Grove, IL, USA). Anti-phospho-EGFR (to activated EGFR) was from BD Biosciences (San Jose, CA, USA), anti-c-MET was from Santa Cruz, and antipTyr antibody was from EMD Millipore (Billerica, MA, USA). Monoclonal and polyclonal anti-integrin b4 were from EMD Millipore, and polyclonal anti-b4 S1356 and b4 S1424 were described. 50, 52 DMBA, BrdU, camptothecin and TPA were from Sigma-Aldrich. Nifuroxazide 45 and ST3-01 (also called ML116) 44 were from Dr DA Frank, Dana-Farber Institute. Lapatinib was from LC Laboratories (Woburn, MA, USA), and SU11274 was from Sigma-Aldrich. CD151 was stably ablated from A431 cells as described.
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CD151-null cells were negatively selected by flow cytometry (using mAb 5C11). Knockdown efficiency was evaluated by flow cytometry and immunoblotting using mAb 1A5.
Skin carcinogenesis experiments and histological examinations CD151-null mice in Sv129 background 34 were crossed four generations onto FVB/N background, to increase chemical carcinogenesis sensitivity. 40 CD151-/-mice were not further backcrossed into FVB/N to avoid kidney pathology complications.
14 All mice used were viable, fertile, and lacked obvious defects in kidneys or elsewhere. Supplementary Figure S4 shows representative diagnostic PCR image and primer sequences used for CD151 genotyping. For two-stage carcinogenesis, 7-week-old female mouse dorsal skin was shaved, and after 1 week treated once with DMBA (100 nmol in 0.2 ml acetone). After another week, mice were treated with TPA (8 nmol in 0.2 ml acetone) twice weekly for 19 more weeks. Control mice were treated with 0.2 ml acetone for 20 weeks. Mice were examined weekly. Growths 41 mm diameter, persisting for X2 weeks, were recorded as tumors.
For 'initiation only' experiments, mice were treated on dorsal skin once (DMBA, 100 nmol) or with acetone alone and killed after 24 h. To assess apoptosis, skin sections were stained with antiactive caspase-3 (R&D Systems, Minneapolis, MN, USA) followed by biotinylated anti-rabbit immunoglobin-G and horseradish peroxidase-conjugated ABC reagent (Vector Laboratories, Burlingame, CA, USA). For 'promotion only' experiments, 8-week-old female mice were treated twice weekly for 2 weeks with TPA (8 nmol) or acetone vehicle and killed after another 24 h. Some mice were injected intraperitoneally with BrdU (2 mg per mouse) in phosphatebuffered saline 2 h prior to killing. Dorsal skin was formalin-fixed, paraffinembedded, sectioned at 4 mm, stained with hematoxylin and eosin and anti-BrdU antibody (BD Biosciences-Pharmingen, San Jose, CA, USA), and then with biotinylated anti-mouse immunoglobin-G and horseradish peroxidase-conjugated ABC reagent (Vector Laboratories). Hematoxylin and eosin-stained skin thickness was measured by micrometer. To determine epidermal cell proliferation, BrdU-positive cells were counted, per unit area. Paraffin sectioning and hematoxylin and eosin and immunohistochemical staining were performed by Harvard Medical School Figure 7 . CD151 affects b4 distribution and phosphorylation. (a) Mouse tumor-derived cell lines were permeabilized and stained for integrin b4. (b) Keratinocytes were isolated from wild-type and null mice and then cultured for a few weeks before integrin b4 subunit staining, bar ¼ 5 mm. (a and b) Linear staining intensity, across the diameter of representative cells, was measured using the Image J program (from NIH). (c) Human A431 cells, stably ablated for CD151, were treated with TPA (50 ng/ml) or EGF (100 ng/ml) for 5 min and 1 h, and then blotted for the indicated proteins, using antibodies for b4-S1424, b4-S1356 and total b4. KD, knockdown; WT, wild type.
Histology Core. All treatments were approved by Dana-Farber Animal Care Committee and followed NIH guidelines.
In vitro tumor and keratinocyte cultures
To establish mouse tumor lines, specimens were collected (after 20 weeks DMBA/TPA treatment), minced and resuspended in collagenase (Worthington Biochemical, Lakewood, NJ, USA, CLS3 type; 200 U/ml) in Medium-199 plus gentamycin (5 mg/ml). After 4 h at 37 1C, suspended cells were cultured in Dulbecco's modified Eagle's medium/F12 medium.
Mouse primary keratinocytes were isolated and cultured as described. 77 Briefly, newborn mouse skin specimens were trypsinized (0.25% trypsin, Invitrogen, Eugene, OR, USA) for 8-10 h at 4 1C, and epidermis was separated from the dermis. Isolated keratinocytes were plated (60 cm dishes), precoated with collagen type I (BD Biosciences), and containing keratinocyte medium (EMEM; Fisher Scientific, Cambridge, MA, USA) supplemented with 0.1 mM monoethanolamine, 0.1 mM phosphoryl ethanolamine, 0.5 mM hydrocortisone at 37 1C in 5% CO 2 . After 5 h, unattached cells were removed by phosphate-buffered saline washing, and attached cells were further cultured in media minus growth factors. Twenty-four hours later, DMBA (30 nM) was added. Apoptosis was determined using Cell Death Detection ELISA kit (Roche Molecular Biochemicals, Mannheim, Germany) and proliferation was determined using MTT (3-(4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide) assay (Roche Diagnostics, Indianapolis, IN, USA), and by cell counting (Countless automated counter, Invitrogen).
Protein lysate preparation
Cell lines were lysed in 50 mM HEPES, 150 mM NaCl, 5 mM MgCl 2 , 1% Triton X-100 and protease inhibitor cocktail. Excised mouse dorsal skin (2 Â 2 cm 2 ) was placed on ice-cold glass, epidermis was removed with a blade, and then tissue was lysed in buffer containing 50 mM Tris-HCl (pH 8.6), 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenymethylsulfonyl fluoride and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). After 10 min at 4 1C, lysates were snap-frozen in liquid nitrogen, thawed and centrifuged (14,000g, 15 min, 4 1C). Supernatant was resolved on 8-12% SDS/polyacrylamide gels, prior to immunoblotting.
Immunofluorescence microscopy
For confocal analyses, cells on coverslips were stained with primary, then secondary antibody (Alexa 488 or Alexa 594-conjugated goat anti-mouse or anti-rat) alone or combined (Invitrogen). Cells were visualized using Leica SP5X laser-scanning confocal microscope (Leica Microsystems, Chicago, IL, USA). . Scheme for CD151 contributions to chemical carcinogenesis in skin. Stimulation of epidermoid cells by EGF and TPA, through EGFR and PKCa, is enhanced when CD151 is present. Signaling is weakened when CD151 is absent, as evidenced by increased potency of agents inhibiting EGFR, PKCa, JAK2/TYK2 and STAT3. CD151 recruits PKC into proximity with b4 integrin. The b4 cytoplasmic tail has previously been linked to JAK2-STAT3 activation. 26 It remains to be determined the extent to which CD151-and PKCa-dependent b4 S1424 phosphorylation directly contributes to STAT3 activation and skin oncogenesis. Results obtained here support previously demonstrated links of STAT3 to skin tumor initiation, promotion and progression. 42, 43 CD151 in human and mouse skin cancer Q Li et al
